Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis
Authors
Keywords
-
Journal
Lancet Microbe
Volume 4, Issue 11, Pages e883-e892
Publisher
Elsevier BV
Online
2023-11-02
DOI
10.1016/s2666-5247(23)00194-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- (2022) Obbina Abani et al. LANCET
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
- (2022) Jennifer Hammond et al. NEW ENGLAND JOURNAL OF MEDICINE
- The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans
- (2022) Yueh-Ming Loo et al. Science Translational Medicine
- Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons
- (2022) Philip L. Tzou et al. PLoS One
- Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
- (2022) Hugh Montgomery et al. Lancet Respiratory Medicine
- Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis
- (2022) Kaiming Tao et al. Microbiology Spectrum
- Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19
- (2022) Flonza Isa et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
- (2022) Adit A. Ginde et al. Lancet Respiratory Medicine
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
- (2021) Angélica Jayk Bernal et al. NEW ENGLAND JOURNAL OF MEDICINE
- REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
- (2021) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
- (2021) Deborah Cromer et al. Lancet Microbe
- COVID-19: towards understanding of pathogenesis
- (2020) Wei Cao et al. CELL RESEARCH
- Fitting Linear Mixed-Effects Models Usinglme4
- (2015) Douglas Bates et al. Journal of Statistical Software
- Conducting Meta-Analyses inRwith themetaforPackage
- (2015) Wolfgang Viechtbauer Journal of Statistical Software
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started